Zanamivir (Glaxo Wellcome)

Area of Science:

• Pharmacology
• Virology
• Drug Development

Background:

• Zanamivir is a neuraminidase inhibitor developed by Glaxo Wellcome for influenza treatment.
• Administered via inhaler directly to the respiratory tract, minimizing systemic side effects.
• Neuraminidase inhibitors are considered technically vaccines, working by stimulating an immune response to prevent viral spread.

Purpose of the Study:

• To document the development, regulatory approval, and market launch of zanamivir (Relenza).
• To track the drug's progress through regulatory bodies including the FDA and Canadian HPB.
• To report on market reception and sales predictions for zanamivir.

Main Methods:

• Review of regulatory submissions and approvals in various countries (Australia, New Zealand, UK, US, Canada, Japan, Europe).
• Monitoring of FDA advisory committee meetings and discussions regarding zanamivir's approval.
• Analysis of financial market predictions for zanamivir sales.

Main Results:

• Zanamivir (Relenza) launched in multiple countries, including the US in October 1999.
• Received FDA approval for influenza A and B treatment in July 1999 after initial advisory committee concerns.
• Canadian Health Protection Branch approval granted in November 1999.
• Sales forecasts varied, with some predicting up to US$400 million by 2003.

Conclusions:

• Zanamivir successfully navigated regulatory hurdles to become a globally available influenza treatment.
• The drug's inhaled administration offers a targeted approach to influenza therapy.
• Despite initial regulatory challenges, zanamivir demonstrated significant market potential and sales expectations.